Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Qiagen N.V. (QGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 7,808,672
  • Shares Outstanding, K 225,880
  • Annual Sales, $ 1,338 M
  • Annual Income, $ 80,400 K
  • 36-Month Beta 1.15
  • Price/Sales 5.83
  • Price/Cash Flow 15.99
  • Price/Book 3.21

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.82 +5.33%
on 07/06/17
35.26 -1.96%
on 06/22/17
-0.26 (-0.75%)
since 06/21/17
3-Month
29.25 +18.19%
on 04/24/17
35.26 -1.96%
on 06/22/17
+5.88 (+20.49%)
since 04/21/17
52-Week
23.70 +45.88%
on 07/25/16
35.26 -1.96%
on 06/22/17
+10.90 (+46.07%)
since 07/21/16

Most Recent Stories

More News
Best Relative Performance in the Life Sciences Tools & Services Industry Detected in Shares of Qiagen Nv (QGEN, NEO, A, BRKR, TMO)

We looked at the Life Sciences Tools & Services industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength....

A : 61.37 (+0.64%)
TMO : 182.18 (+0.35%)
BRKR : 29.15 (+0.76%)
NEO : 9.11 (-0.44%)
QGEN : 34.57 (+0.06%)
QIAGEN N.V. to Report Second Quarter and First Half of 2017 Results

QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans as previously announced to release its report on results for the second quarter and first half of 2017 on Thursday, July 27, at approximately 22:00 Central...

QGEN : 34.57 (+0.06%)
Best Relative Performance in the Life Sciences Tools & Services Industry Detected in Shares of Pra Health Scien (PRAH, A, Q, QGEN, PKI)

We looked at the Life Sciences Tools & Services industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength....

A : 61.37 (+0.64%)
Q : 91.15 (+0.94%)
QGEN : 34.57 (+0.06%)
PRAH : 75.37 (-1.14%)
PKI : 69.52 (+0.09%)
NanoString Appoints J. Chad Brown as Senior Vice President of Sales and Marketing

NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that J. Chad Brown has been appointed Senior...

QGEN : 34.57 (+0.06%)
NSTG : 15.84 (-0.69%)
French health system approves reimbursement of QIAGEN's QuantiFERON latent TB test

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that France's Ministry of Health and Social Affairs has approved reimbursement by the national health insurance system for QIAGEN's...

QGEN : 34.57 (+0.06%)
Electrophoresis Market by Product (Gel Electrophoresis , Capillary Electrophoresis, Reagents, Geldoc, Imaging), Application (Diagnostic, Reasearch, Quality Control), End User - Global Forecast to 2022

Research and Markets has announced the addition of the "Electrophoresis Market by Product (Gel Electrophoresis , Capillary Electrophoresis, Reagents, Geldoc, Imaging), Application (Diagnostic, Reasearch,...

A : 61.37 (+0.64%)
HBIO : 2.55 (+2.00%)
MRK : 62.63 (-0.49%)
SHMZF : 15.7500 (+0.94%)
TDY : 135.97 (+0.37%)
LZAGF : 225.4600 (+1.33%)
QGEN : 34.57 (+0.06%)
Genetic Testing Market 2016-2024: Prenatal & Newborn Genetic Testing, Pharmacogenomic Testing & Predictive Diagnostics - Global Strategic Business Report 2017

Research and Markets has announced the addition of the "Genetic Testing - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada,...

NTRA : 9.69 (-0.62%)
ABT : 50.84 (-0.02%)
DGX : 109.39 (-0.24%)
CPHD : 52.95 (unch)
ILMN : 172.75 (+0.45%)
LMNX : 20.71 (-0.86%)
QGEN : 34.57 (+0.06%)
SQNM : 2.39 (-0.42%)
LH : 156.55 (+0.28%)
TBIOD : 6.8000 (-1.45%)
PKI : 69.52 (+0.09%)
QIAGEN Strengthens Cancer Research Foothold on New License

QIAGEN N.V. (QGEN) has received a worldwide license for biomarkers to be used in identifying patients who may have benefited from immune-oncology (I-O) therapies in cancer treatment.

AXDX : 27.60 (-0.18%)
QGEN : 34.57 (+0.06%)
ALGN : 158.87 (-0.81%)
INGN : 95.22 (-1.58%)
QIAGEN receives U.S. FDA approval for cytomegalovirus (CMV) testing on automated QIAsymphony platform

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received premarket approval from the U.S. Food and Drug Administration (FDA) for its automated artus® CMV QS-RGQ MDx kit for...

QGEN : 34.57 (+0.06%)
Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo

Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior...

MRK : 62.63 (-0.49%)
QGEN : 34.57 (+0.06%)
SGEN : 54.39 (+0.46%)
BMY : 55.65 (+0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.

See More

Support & Resistance

2nd Resistance Point 34.81
1st Resistance Point 34.69
Last Price 34.57
1st Support Level 34.45
2nd Support Level 34.33

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.